Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT followed by CROSS chemoradiotherapy for oligometastatic oesophageal or gastro-oesophageal junction adenocarcinoma
NL-OMON23939Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin, folinic acid, fluorouracil, carboplatin and 1 more in adenocarcinoma of the lower esophagus and gastroesophageal adenocarcinoma, sponsored by Erasmus MC. Primary endpoint: Tolerability of the combined regimens. Started Jan 2021; status: recruiting.
02
Drugs
docetaxeloxaliplatinfolinic acidfluorouracilcarboplatin
03
Conditions
adenocarcinoma of the lower esophagusgastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON23939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23939.